文献速递心律失常肺血管病与心包/心肌炎

胺碘酮与房颤患者肺毒性:以色列全国性研究

Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study.
PubMed 文献 · Eur Heart J · 2024-01-01

以色列全国性队列研究纳入1999–2021年新发房颤患者,将胺碘酮暴露者与未暴露者按年龄、性别、族裔和房颤病程1:1匹配,最终分析6039对匹配患者。中位年龄73.3岁,女性51.6%,平均随访4.2年。经IPTW校正后,胺碘酮与间质性肺病(ILD)风险无显著关联(HR 1.45,95%CI 0.97–2.44,P=0.09),与原发性肺癌无关(HR 1.18,95%CI 0.76–2.08,P=0.53),但与全因死亡风险降低相关(HR 0.65,95%CI 0.60–0.72,P<0.001)。

要点

  • 低剂量胺碘酮与ILD风险呈边缘性增加趋势,但绝对风险增幅临床可忽略。
  • 胺碘酮未增加原发性肺癌风险。
  • 胺碘酮暴露与全因死亡风险降低相关。

核心结论

  • 在当前低剂量胺碘酮治疗时代,胺碘酮暴露与ILD风险呈增加趋势(15%–45%),但绝对风险变化临床可忽略(最大1.8%)。
  • 胺碘酮不增加原发性肺癌风险,且与全因死亡风险降低相关。

研究设计与样本

  • 胺碘酮暴露者与未暴露对照按年龄、性别、族裔和房颤诊断时长1:1匹配,仅纳入随访期间胺碘酮治疗一致的匹配对。
  • 最终队列包括6039例胺碘酮暴露患者及匹配对照,中位年龄73.3岁,女性51.6%。
  • 采用有向无环图和逆概率治疗加权(IPTW)建模,排除既往ILD或原发性肺癌患者。

主要发现

  • 平均随访4.2年,ILD发生于242例(2.0%)患者;IPTW后胺碘酮与ILD无显著关联(HR 1.45,95%CI 0.97–2.44,P=0.09)。
  • 随访第2至8年间,胺碘酮暴露者ILD相对风险轻微升高(最大RR 1.019)。
  • 原发性肺癌发生于97例(0.8%)患者;IPTW后胺碘酮与PLC无关(HR 1.18,95%CI 0.76–2.08,P=0.53)。
  • 全因死亡发生于2185例(18.1%)患者;IPTW后胺碘酮与死亡风险降低相关(HR 0.65,95%CI 0.60–0.72,P<0.001)。
  • 结果在多种敏感性分析中一致。

临床怎么用

  • 对于房颤患者,低剂量胺碘酮的ILD绝对风险增幅较小,但仍需保持临床监测。
  • 胺碘酮不增加肺癌风险,不应以此作为限制使用的依据。
  • 胺碘酮与全因死亡风险降低相关,支持其在房颤中的合理应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Amiodarone-related interstitial lung disease (ILD) is the most severe adverse effect of amiodarone treatment. Most data on amiodarone-related ILD are derived from periods when amiodarone was given at higher doses than currently used. METHODS: A nationwide population-based study was conducted among patients with incident atrial fibrillation (AF) between 1 December 1999 and 31 December 31 2021. Amiodarone-exposed patients were matched 1:1 with controls unexposed to amiodarone based on age, sex, ethnicity, and AF diagnosis duration. The final patient cohort included only matched pairs where amiodarone therapy was consistent throughout follow-up. Directed acyclic graphs and inverse probability treatment weighting (IPTW) modelling were used. Patients with either prior ILD or primary lung cancer (PLC) were excluded. The primary outcome was the incidence of any ILD. Secondary endpoints were death and PLC. RESULTS: The final cohort included 6039 amiodarone-exposed patients who were matched with unexposed controls. The median age was 73.3 years, and 51.6% were women. After a mean follow-up of 4.2 years, ILD occurred in 242 (2.0%) patients. After IPTW, amiodarone exposure was not significantly associated with ILD [hazard ratio (HR): 1.45, 95% confidence interval (CI): 0.97, 2.44, P = 0.09]. There was a trivial higher relative risk of ILD among amiodarone-exposed patients between Years 2 and 8 of follow-up [maximal risk ratio (RR): 1.019]. Primary lung cancer occurred in 97 (0.8%) patients. After IPTW, amiodarone was not associated with PLC (HR: 1.18, 95% CI: 0.76, 2.08, P = 0.53). All-cause death occurred in 2185 (18.1%) patients. After IPTW, amiodarone was associated with reduced mortality risk (HR: 0.65, 95% CI: 0.60, 0.72, P < 0.001). The results were consistent across a variety of sensitivity analyses. CONCLUSION: In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Tsaban G, Ostrovsky D, Alnsasra H, et al. Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study. Eur Heart J. 2024. PMID: 37939798. doi:10.1093/eurheartj/ehad726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。